The bonds will come due 2025. Sosei Heptares will use the funds to pursue growth initiatives. Those initiatives include a potential acquisition, investments in its drug discovery platform, and licensing late-stage clinical assets to build its presence in the Japanese market.
Sosei has a pipeline of candidates in gastroenterology, immuno-oncology, inflammation and other rare/specialty indications.
More articles on surgery centers:
Hybrid ASC is up and running with 43 cardiac partners: 6 things to know
Florida ASC closes real-estate sale-leaseback transaction: 4 details
Ohio health system acquires surgery center for $21M
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
